Clinical trials: Injections
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been…
- Trial name
- QWINT-4 (NCT05462756)
- Testing
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Where
- 81 sites in United States, Argentina and 6 more
- Volunteers
- 730 people
- Sponsor
- Eli Lilly and Company
Pain
Comparison of Exparel to Bupivacaine With Dexamethasone in TAP Block
The purpose of this study is to compare the efficacy and duration of bupivacaine extended-release liposome injection (Exparel) versus bupivacaine with dexamethasone in transversus abdominis plane (TAP) blocks for patients…
- Trial name
- TapBlock (NCT02179892)
- Testing
- Bupivacaine Extended-Release Liposome Injection (Exparel), Bupivacaine and Dexamethasone Injection, IV Acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Colette Curtis MD
Influenza, Human
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates
This research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics.
- Trial name
- NCT04565353
- Testing
- Flu shot text messages
- Where
- 2 sites in United States
- Volunteers
- 74,811 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Acromegaly
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.
- Trial name
- DOPAACRO 002 (NCT03045302)
- Testing
- BIM23B065
- Where
- 6 sites in Belgium, Hungary and 2 more
- Volunteers
- 4 people
- Sponsor
- Ipsen
Diabetes Mellitus, Type 1
Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes
This study is evaluate the superior efficacy of a Continuous Glucose Monitor (CGM)-based advisory system in Type 1 Diabetes Mellitus (T1DM), as compared to Sensor Augmented Mode (SAM) therapy, and with characterizing the impact…
- Trial name
- DSS-2 (NCT04443153)
- Testing
- Personalized Feedback, Decision Support System, Sensor Augmented Mode
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Virginia
Non Infectious Uveitis
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS).
- Trial name
- NCT03711929
- Testing
- DE-109 Intravitreal Injections, DE-109 Intravitreal Injections (Open Label)
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 145 people
- Sponsor
- Santen Inc.
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
This is a pilot study utilizing Marqibo® (vincristine sulfate liposome injection) combined with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute lymphoblastic leukemia (ALL).
- Conditions
- ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
- Trial name
- NCT02879643
- Testing
- Marqibo
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Macular Edema Secondary to Branch Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- Blossom (NCT01976338)
- Testing
- Ranibizumab 0.5 mg
- Where
- 33 sites in China, Hong Kong and 4 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Juvenile Rheumatoid
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug: Unknown adverse drug reactions (especially important adverse…
- Trial name
- NCT01412021
- Volunteers
- 375 people
- Sponsor
- AbbVie
Postpartum Depression
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
- Trial name
- NCT02285504
- Testing
- SAGE-547
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Healthy
A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants
This study is being conducted to determine the side effects related to LY3493269 given as a single injection to healthy participants.
- Trial name
- NCT04178733
- Testing
- LY3493269 - SC, LY3493269 - IV
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with…
- Trial name
- GALLEGO (NCT03972709)
- Testing
- Galegenimab
- Where
- 72 sites in United States
- Volunteers
- 372 people
- Sponsor
- Genentech, Inc.
Osteoarthritis
Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee
The purpose of this study is to determine whether intra-articular injection of Monovisc® hyaluronic acid provides symptomatic relief of osteoarthritis of the knee.
- Trial name
- NCT00653432
- Testing
- Monovisc®, Saline
- Where
- 31 sites in United States, Canada
- Volunteers
- 369 people
- Sponsor
- Anika Therapeutics, Inc.
Dyssynergic Defaecation, Evacuation Disorder
Infracoccygeal Botox for Dyssynergia
Background: Constipation is a common problem, affecting up to 20% of the population during their lifetime. Some patients respond poorly to standard treatments such as laxatives.
- Conditions
- Dyssynergic Defaecation, Evacuation Disorder, Anismus, Defecation Disorder
- Trial name
- NCT04879524
- Testing
- Percutaneous infracoccygeal Botulinum toxin injection to puborectalis
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Queen Mary University of London
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS
This open-label, dose-response study will evaluate the safety and efficacy of CM4620-IE in patients with acute pancreatitis and accompanying SIRS. The study will consist of two phases.
- Trial name
- NCT03401190
- Testing
- CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- CalciMedica, Inc.
Osteoarthritis of the Knee
Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee
This is an Open-label Study to Assess the Safety of Repeat Dose of FX006 Administered to Patients with Osteoarthritis (OA) of the Knee
- Trial name
- NCT03046446
- Testing
- FX006 32 mg
- Where
- 17 sites in United States
- Volunteers
- 208 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Idiopathic Short Stature
A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)
This is an open-label, multi-center, randomized, two-arm parallel, no-treatment group controlled (only for the first 6 months), Phase 3 study in children with ISS.
- Trial name
- NCT01746862
- Testing
- Saizen®
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Age-related Volume Deficit in the Mid-face
A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula
The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel using cannula in participants seeking correction of age-related volume deficit in the mid-face.
- Trial name
- NCT03438266
- Testing
- JUVÉDERM VOLUMA® XC injectable gel with cannula, JUVÉDERM VOLUMA® XC injectable gel with needle
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Allergan
ADA-SCID, Adenosine Deaminase Deficiency
EZN-2279 in Patients With ADA-SCID
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.
- Conditions
- ADA-SCID, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency
- Trial name
- NCT01420627
- Testing
- EZN-2279, Adagen
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Leadiant Biosciences, Inc.
Diabetes Complications, Diabetes Mellitus
The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes
The goal of this pilot study is to obtain preliminary data on the magnitude of the treatment effect of IVIG on the neuropathic pain and neuropathy severity associated with treatment induced neuropathy (TIND).
- Conditions
- Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
- Trial name
- NCT02915263
- Testing
- IGIV-C, 0.9% Sodium Chloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Beth Israel Deaconess Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.